The p300/CBP-associated factor (PCAF) and related GCN5 bromodomain-containing lysine acetyl transferases are members of subfamily Io ft he bromodomain phylogenetic tree.I terative cycles of rational inhibitor design and biophysical characterization led to the discovery of the triazolopthalazine-based L-45 (dubbed L-Moses)a st he first potent, selective,a nd cell-active PCAF bromodomain (Brd) inhibitor.S ynthesis from readily available (1R,2S)-(À)-norephedrine furnished L-45 in enantiopure form. L-45 was shown to disrupt PCAF-Brd histone H3.3 interaction in cells using an anoBRET assay,a nd ac o-crystal structure of L-45 with the homologous BrdP fGCN5 from Plasmodium falciparum rationalizes the high selectivity for PCAF and GCN5 bromodomains.C ompound L-45 shows no observable cytotoxicity in peripheral blood mononuclear cells (PBMC), good cell-permeability,and metabolic stability in human and mouse liver microsomes,supporting its potential for in vivo use.Bromodomains proteins (Brds) bind to acetylated lysines (KAc) through the Brd acetyllysine-binding site.M isregulation of these proteins is linked to the onset and progression of multiple disease states,s uch as cancer.[1] Significant efforts have been made recently to interrogate the role of these targets through the development of chemical probes and inhibitors.[2] Considerable work has focused on the BET family (Brd sub-family II), [3] however non-BET [4] Brds are increasingly receiving the attention of small molecule intervention efforts,w ith the disclosure of more than 10 new chemical probes/inhibitors in 2016. [5] Thep 300/CBP-associated factor,P CAF( KAT2B), is amulti-domain protein containing asingle Brd, an N-terminal domain, and ah istone acetyltransferase (HAT) domain. Known to associate with CBP [6] and p300 [6b] during transcription, misregulation of PCAF has been linked to cancer, [7] HIV infection, [7a, 8] and neuroinflammation. [7a, 9] Despite predictions of high druggability [10] and links with inflammatory disease, [7a, 11] the role of PCAF and, more specifically,c ontributions of the Brd in such disease states are poorly understood. Thedevelopment of asmall molecule modulator of PCAF Brd would provide au seful tool for interrogating this potential therapeutic target and allow for dissociation of the roles of the Brd and enzymatic domains in disease.Initial reports of PCAF Brd inhibitors were focused on disrupting interactions between the HIV-1 peptide TAT-1a nd PCAF Brd.[